VOR: Rounding Bottom detected on 6 Apr 2026

VOR is forming a rounding bottom recovery pattern after collapsing from a 52-week high of $65.80 to $2.62, now trading at $18.05—up 589% from the low and 72% below the recent peak. The setup exhibits strong structure (15/15), solid breakout potential (13/13), and adequate volume (12/12) for an overall quality score of 40, with a 64.77% historical win probability. Price is positioned at the top of a 90-day recovery range, approaching key resistance at $47.60. The 33% weekly gain and sustained 3-month advance of 38% signal accumulation. RSI at 67.79 indicates near-overbought conditions but not yet exhausted. Volume ratio of 1.3 above 20-day average suggests institutional re-engagement during this recovery phase.

On March 30, 2026, Vor Bio reported Q4 2025 financial results and announced dosing of the first patient in the global Phase 3 UPSTREAM SjD registrational trial of telitacicept in primary Sjögren's disease. The company also announced a $75 million private placement on March 27, 2026. This recent capital raise and trial enrollment milestone are driving the pattern formation. On March 31, 2026, Wedbush raised VOR's price target to $15.00 from $9.00, maintaining a neutral rating. Jefferies Financial Group assumed coverage with a buy rating and $50.00 target price. Six analysts rate the stock Buy, four Hold, and one Sell, with consensus price target of $50.67. Sector tailwinds in biotech remain bullish (regime score 0.24), supporting recovery momentum despite broader market bearishness (regime -0.4).

A successful rounding-bottom breakout from current levels would target $19.25 (conservative measure)—representing a 6.7% move—with potential to extend toward $47.60 resistance if momentum accelerates. Volume confirmation is critical: breakout above $19.25 must occur on volume exceeding the 1.3x relative baseline already present. Historical win probability of 64.77% indicates this pattern setup has favorable odds. The invalidation level sits at $6.50 (key support), which represents the prior recovery low; any breakdown below this level negates the pattern thesis and signals a fresh selloff. With RSI at 67.79, the setup may encounter profit-taking near 70, requiring volume thrust to push through resistance zones cleanly.

Short interest stands at 3.4 million shares (9.3% of float), up 160.1% over the past 12 months. The company experienced significant share dilution from a recent secondary offering at $10.00, representing a 47% discount from the prior closing price of $18.80, prompting H.C. Wainwright to revise the price target from $55 to $32. Weiss Ratings maintains a sell rating. The company faces significant financial challenges with no revenue and ongoing losses. An RSU vesting event is scheduled for August 1, 2026, representing potential incremental dilution and insider selling pressure in 120 days. High beta of 1.92 per recent data compounds volatility risk. Biotech sector execution risk remains elevated—clinical trial delays or unfavorable Phase 3 data in telitacicept programs could trigger sharp reversals.